Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...1011121314151617181920...136137»
  • ||||||||||  PBLD328. The MacGyver Approach: Monitoring Quantitative Neuromuscular Function With an iPhone (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_2372;    
    Learning Objective 2 Recognize the impact of myasthenia gravis on anesthetic management specifically during weaning from ventilator and emphasize role of quantitative neuromuscular monitoring.. Learning Objective 3 Understand how to turn an iPhone to quantitative neuromuscular monitoring device when commercially available devices are not available.
  • ||||||||||  PBLD248. The MacGyver Approach: Monitoring Quantitative Neuromuscular Function With an iPhone (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_1582;    
    Learning Objective 2 Recognize the impact of myasthenia gravis on anesthetic management specifically during weaning from ventilator and emphasize role of quantitative neuromuscular monitoring.. Learning Objective 3 Understand how to turn an iPhone to quantitative neuromuscular monitoring device when commercially available devices are not available.
  • ||||||||||  Thymectomy in Myasthenia Gravis (30BC) -  Jun 25, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_404;    
    Not yet recruiting --> Recruiting There is no abstract associated with this presentation.
  • ||||||||||  Journal:  Short-term outcomes of robotic subxiphoid-optical thymectomy. (Pubmed Central) -  Jun 24, 2024   
    There is no abstract associated with this presentation. RST is a safe procedure that provides surgeons with a sufficient view of the anterior mediastinum and causes minimal postoperative pain.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Journal:  Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. (Pubmed Central) -  Jun 24, 2024   
    We report a 65-year-old MuSK-MG patient who presented with impaired eye movements initially, and the symptoms rapidly worsened within a week, affecting the limbs and neck muscles, and had difficulties in chewing and swallowing. Lymphoplasmapheresis did not achieve satisfactory results, but after a cycle of efgartigimod treatment, the patient's symptoms gradually improved and remained in a good clinical state for several months.
  • ||||||||||  Review, Journal:  Myasthenia as the cause of vertical diplopia in the elderly (Pubmed Central) -  Jun 21, 2024   
    Thymectomy is also used for immunomodulatory indications according to the 2023 revised guidelines. Patient-centered treatment goals, patient education and comprehensive information, also via the self-help organization German Myasthenia Society, are essential components of successful treatment of myasthenia.
  • ||||||||||  Review, Journal:  Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis. (Pubmed Central) -  Jun 21, 2024   
    In this review, we provide an overview of key immunopathogenetic processes underlying MG, and discuss on emerging biological drugs targeting them. We also discuss on future direction of research to address the need for patients' stratification in endotypes according with genetic and molecular biomarkers for successful clinical decision making within precision medicine workflow.
  • ||||||||||  Journal:  Improving Outcome in Severe Myasthenia Gravis and Guillain-Barr (Pubmed Central) -  Jun 19, 2024   
    This case emphasizes the diagnostic challenges of bulbar-type DSN-MG and underscores the value of a VFSS with edrophonium for diagnosing this condition. Unlike myasthenia gravis, the recovery period is prolonged in Guillain-Barr
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. (Pubmed Central) -  Jun 19, 2024   
    This study provides a fresh perspective on the management of genital malacoplakia. Tocilizumab is safe and effective in improving the MG-ADL score and reducing prednisone dose in refractory AChR-Ab+ gMG, suggesting tocilizumab has the potential to be a valuable therapeutic option for such patients.
  • ||||||||||  prednisone / Generic mfg., azathioprine / Generic mfg.
    Journal, Real-world evidence, Real-world:  Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy. (Pubmed Central) -  Jun 19, 2024   
    These issues may be addressed by the new treatments currently being developed. To date, more studies are needed to address the heterogeneity, quality, and generalizability of the existing data and to evaluate patterns of use, efficacy, and safety of new or emerging therapies for MG.
  • ||||||||||  Review, Journal, Surgery:  Loco-Regional Anesthesia for Pain Management in Robotic Thoracic Surgery. (Pubmed Central) -  Jun 19, 2024   
    The review concludes that a multimodal analgesia strategy, potentially incorporating several of these techniques, may offer the most effective approach for managing perioperative pain in robotic thoracic surgery. Future directions include refining these techniques through technological advancements like ultrasound guidance and exploring the long-term impacts of loco-regional anesthesia on patient recovery and surgical outcomes in the context of robotic thoracic surgery.
  • ||||||||||  Which combination of comorbidity makes migraine treatment impossible? A graphical approach () -  Jun 18, 2024 - Abstract #AHS2024AHS_411;    
    Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
  • ||||||||||  KYV-101 / Kyverna
    Journal, CAR T-Cell Therapy:  Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. (Pubmed Central) -  Jun 17, 2024   
    KYV-101 CAR T cells were well tolerated with only low-grade cytokine release syndrome. This report of successful use of anti-CD19 CAR T cells in treatment-refractory SPS supports continued exploration of this approach in SPS and other B cell-related autoimmune disorders.
  • ||||||||||  Review, Journal, Surgery:  Relevance of robotic surgery for thymoma: a narrative review. (Pubmed Central) -  Jun 17, 2024   
    Robotic thymothymectomy is safe with effective and promising long-term results and oncological and surgical outcomes in patients with thymoma. Robotic thymectomy can become the standard procedure in patients with early-stage thymomas.
  • ||||||||||  Review, Journal:  Thymectomy for juvenile myasthenia gravis: a narrative review. (Pubmed Central) -  Jun 17, 2024   
    At present, the data available is unable to support conclusions regarding which surgical approach is superior; however, minimally invasive approaches may be non-inferior while offering superior cosmesis and decreased morbidity. Higher-level investigation through the use of multi-institutional databases and randomized prospective trials is warranted in order to understand which child warrants thymectomy, at what point in their disease course and their development, and which surgical approach will optimize postoperative outcomes.
  • ||||||||||  Journal:  Lady With the Blue Hair: An Atypical Cause of Myasthenic Crisis. (Pubmed Central) -  Jun 13, 2024   
    As more evidence for new precipitating factors of myasthenic crises develops, it is crucial for physicians to quickly identify signs and symptoms of a crisis so appropriate intervention can occur in a time-sensitive manner. In addition, myasthenia gravis patients should be made aware to be cautious of precipitating factors of a crisis, including but not limited to new beauty products.
  • ||||||||||  Journal:  Office-based respiratory assessment in patients with generalized myasthenia gravis. (Pubmed Central) -  Jun 12, 2024   
    There were significant correlations between MIPs, FVC and SNIPs; between MGII/MG-QOL15 and UCSD-SOB/MRC-DS and between ESS and respiratory scales in the whole group. Our data suggests that office-based respiratory measurements are a useful screening method for stable MG patients, even when presenting with minimal respiratory symptoms and no significant disability.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Checkpoint inhibition:  Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report. (Pubmed Central) -  Jun 12, 2024   
    This case underscores the significance of recognizing and addressing the "Terrible Triad" of IRAEs in patients receiving ICIs. Healthcare providers should maintain a high index of suspicion for overlapping toxicities and promptly initiate appropriate interventions.